XOMA Royalty’s Post

According to BioWorld News, January biopharma deals exceed $26B, marking sixth-highest month Biopharma deals in January reached $26.97 billion, marking the sixth-highest month in BioWorld’s records going back to 2016. It is an increase of nearly 25% from the $21.64 billion in deals in January 2023 and also is up from December. Value the first month of the year is more than 2023’s average monthly value of $18.14 billion, and likewise more than the average monthly value of any previous year. While M&As are up 132.61% from January 2023’s $2.8 billion, the $6.52 billion value in the first month of 2024 falls short of December 2023’s $52.02 billion and the 2023 average of $11.65 billion per month.

Following a downturn in M&A activity during 2022 and 2023, the biopharma industry is increasing its level of dealmaking. Dive in: https://ow.ly/sONO30sCKAN

Following a downturn in M&A activity during 2022 and 2023, the biopharma industry is increasing its level of dealmaking. Dive in: https://ow.ly/zWot30sCKYf

📣 Join Hagen Rogers on a wild story about an M&A deal that went bad. This eye-opening video sheds light on the valuable lessons learned when Eclat Pharmaceuticals was lured into a 100% contingency payment offer. Watch now for insightful perspectives and crucial lessons for Sellers. https://lnkd.in/d7yHrAHd   #MandA #BusinessInsights #EclatPharmaceuticals #FlamelTechnologies

ChargePoint Holdings, Inc., Tarsus Pharmaceuticals, Inc., The AES Corporation are the top 3 stocks with the potential to double your money in under 3 years. Uncover expert insights and investment strategies for maximizing your returns in the stock market: Read on: https://lnkd.in/g7uAhKih #stocks #stockmarkett #stockinvesting #stocktobuy #stockstowatch #doublemoney #double #goodreturns #returnoninvestment #investing #stockmarketindia #trending #trendingnow #virals #viralreelsシ #viralpost

Dealmaking is picking up... Following a downturn in M&A activity during 2022 and 2023, the biopharma industry is increasing its level of dealmaking. Dive in: https://ow.ly/rPZJ30sCOX8

NATCO PHARMA is looking like an amazing opportunity to me now at 812🔥 1) Valuation wise very undervalued at a PE of just 12 2) Natco Pharma is the most undervalued stock is the Pharma sector at A PE of just 12 3) Excellent consistent growth in earnings 4) Very good 10 Yr compounded profit growth of 25% 5) FIIs have significantly increased stake from 11.03% to 12.82% QOQ 6) Currently there is a huge valuation gap, and stock is very undervalued. 3 year average PE of 33 VS Current PE of 12

Investors, important. As I was right about Swvl Holdings Corp. (SWVL) whose shares rose over 2300% in just a few months, that's what I claimed and it was true. So now I want to draw your attention to another company that is at the beginning of a part of history with its inventions in the field of biopharmaceuticals. It is Tonix Pharmaceuticals Holding Corp. (TNXP). I'm sure these shares will rise above 5000% very soon. And that this growth will continue in the future. https://lnkd.in/efnK_u_G https://lnkd.in/eQ-XtthA https://lnkd.in/e3J9c39e #TonixPharmaceuticalsHoldingCorp. #TNXP

This small-cap pharma stock surged with a 22% YoY increase in PAT, hitting ₹461 crore! Watch till the end to find out which stock it is. Don’t forget to save and share this with your fellow traders. #ICICIdirect #smallcap #pharma #stockmarketindia

📉📈 #MarketToday - #AkumsIPO | The Rs 1,856.74 crore-initial public offering (#IPO) of #AkumsDrugs and #Pharmaceuticals kicked off for bidding today (July 30). ➡ The #pharma player will be offering its #shares in the fixed price band of Rs 646-679 apiece, with a lot size of 22 #equityshares and its multiples thereafter. The issue is open for bidding till Thursday, August 1 and the latest #GMP is Rs 211. Should you subscribe? Here's what brokerages say 👉 https://lnkd.in/grc_kDCE